As Stent Business Falls Apart, Field Gets More Crowded

Health and Healthcare

Published: October 11, 2007 5:57 am

Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns about whether the product has long-term risks or whether it is more effective than drug treatments.

Stents, the little metal supports that keep blocked arteries open, have come under whithering criticism in the medical community. The negative press has almost ruined the business for Boston Scientific (BSX) and Johnson & Johnson (JNJ) BSX, which relies heavily on the product has watched its stock fall from $27 in December 2005 to its current level below $15.

The stent companies hoped that if they coated their products with drugs that would prevent clotting where they were installed, it would help. It does not appear to have worked out that way.

This much is for certain. As demand for stents slackens, the number of players in the market is moving up.

Douglas A. McIntyre

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.